RE:WOWPerhaps the most interesting thing about this is the timing; the piece mentions that ONC will be entering phase III trials in 2020, however, based on some past trials, my guess is people are expecting the phase III trial to be a lengthy one... this is why the work around the biomarker of T-cell clonality was soooooooooooo important. This can be measured in a matter of a few weeks... not the many, many months past studies were conducted for in order to measure progression free survival... I think once people realize the speed at which ONC can complete a phase III study, the share price will move much more rapidly toward fair value.